A detailed history of Profund Advisors LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 14,711 shares of ARVN stock, worth $275,537. This represents 0.01% of its overall portfolio holdings.

Number of Shares
14,711
Previous 15,954 7.79%
Holding current value
$275,537
Previous $424,000 14.62%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$23.66 - $32.73 $29,409 - $40,683
-1,243 Reduced 7.79%
14,711 $362,000
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $125,846 - $207,858
5,145 Added 47.6%
15,954 $424,000
Q1 2024

May 08, 2024

BUY
$36.38 - $52.31 $209,112 - $300,677
5,748 Added 113.57%
10,809 $446,000
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $71,815 - $214,232
5,061 New
5,061 $208,000
Q1 2023

May 11, 2023

BUY
$26.15 - $37.26 $237,206 - $337,985
9,071 New
9,071 $247,000
Q2 2022

Aug 01, 2022

SELL
$36.01 - $74.24 $144,832 - $298,593
-4,022 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$60.27 - $81.57 $16,935 - $22,921
-281 Reduced 6.53%
4,022 $271,000
Q4 2021

Feb 08, 2022

BUY
$65.85 - $96.21 $18,569 - $27,131
282 Added 7.01%
4,303 $353,000
Q3 2021

Nov 12, 2021

BUY
$73.2 - $107.87 $24,229 - $35,704
331 Added 8.97%
4,021 $330,000
Q2 2021

Aug 12, 2021

BUY
$60.45 - $84.26 $26,900 - $37,495
445 Added 13.71%
3,690 $285,000
Q1 2021

May 14, 2021

BUY
$58.19 - $91.37 $21,588 - $33,898
371 Added 12.91%
3,245 $214,000
Q4 2020

Feb 09, 2021

BUY
$20.19 - $84.93 $58,026 - $244,088
2,874 New
2,874 $244,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.